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Abstract
Objectives—To analyse mortality, loss to follow-up (LTFU) and retention on antiretroviral
treatment (ART) in the first year of ART across all age-groups in the Malawi national ART
programme.
Design—Cohort study including all patients who started ART in Malawi’s public sector clinics
between 2004 and 2007.
Methods—ART registers were photographed, information entered into a database and merged
with data from clinics with electronic records. Rates per 100 patient-years and cumulative
incidence of retention were calculated. Subhazard ratios (sHR) of outcomes adjusted for patient
and clinic level characteristics were calculated in multivariate analysis, applying competing risk
models.
Results—A total of 117,945 patients contributed 85,246 person-years: 1.0% were infants <2
years, 7.4 % children 2–14, 7.5% young people 15–24, and 84.2% adults 25 years and above.
Sixty percent of patients were female: women outnumbered men from age 14 to 35 years.
Mortality and LTFU were higher in men from age 20 years. Infants and young people had the
highest rates per 100 person-years for mortality (23.0 and 19.4) and LTFU (24.7 and 19.3), and the
highest adjusted relative risks compared to age group 25–34 years: sHRs were 1.37 (95%CI 1.17–
1.60) and 1.17 (95%CI 1.10–1.25) for death and 1.37 (95%CI 1.18–1.59) and 1.27 (95%CI 1.19–
1.35) for LTFU, respectively.
Conclusion—In this country-wide study patients aged 0–1 and 15–24 years had the highest risk
of death and LTFU, and from age 20 and older men were at higher risk than women. Interventions
to improve outcomes in these patient groups are required.
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INTRODUCTION
Antiretroviral (ART) programmes rapidly scaled up in many countries in Sub-Saharan
Africa in recent years. To promote this process, WHO and UNAIDS developed a public
health approach, based on clinical decision making, standardized and simplified treatment
protocols, regimes, decentralised and free services at the point of care and a coordinated
response to the epidemic, including a single monitoring and evaluation system [1, 2].
Monitoring of ART outcomes has been challenging [3].The lack of individual-level data is a
major limitation of reports of many national ART programmes. Though large databases have
been analysed [4–9], to our knowledge Thailand is the only country that has published
nation-wide data at the level of the individual [10, 11]. Rwanda collected data on a
representative sample of patients on ART [12]. With few exceptions [6], reports of adults
and children are published separately, making a direct comparison of outcomes within a
programme difficult.
By the end of 2009 Malawi achieved an ART coverage of 46%, based on the eligibility
criteria of the 2010 WHO guidelines, using the public health approach [3]. The quality of the
national ART monitoring and evaluation system has been assessed [13–15] and an analysis
of aggregated data including adults and children concluded that the rapid ART scale up
between 2004 and 2006 was successful [16]. However, the use of quarterly and facility-level
data limited this analysis to cumulative outcomes and survival probabilities at 6 and 12
months.
Our aim was to analyse ART outcomes across all age groups and to examine factors related
to progression to death, loss to follow-up (LTFU) and programme retention, based on
individual-level data from the national ART register.
METHODS
The scale up of ART in Malawi
The national scale up of ART was planned and implemented strategically [17]. Clinics are
staffed with at least one clinician (usually clinical officer grade), one nurse (who is certified
to provide ART), a counsellor and a clerk. Clinics dispense ART free of charge and start 25
(low), 50 (medium) or 150 (high burden sites) new patients on treatment each month.
Initially, only first line drugs were supplied, consisting of fixed dose combination (FDC)
tablets of stavudine (d4T) 30mg or 40mg, lamivudine (3TC) 150 mg and nevirapine (NVP)
200 mg (Triomune™ 30 or 40). Alternative drugs, including efavirenz (EFV), were only
available for NVP associated toxicity, and these drugs as well as paediatric ART were
limited to central hospitals. By December 2005, 98 sites had started patients on ART,
including all Central and District Hospitals. The revised 2006 national ART guidelines
recommended Triomune™ 30 for all patients, children could be started in all sites and the
WHO paediatric 4 stage system was adopted [18].
Patients register at the ART clinics, are clinically staged and receive cotrimoxazole (CTX)
prophylaxis except adults in WHO stage 1. Patients are deemed eligible for ART if they are
in WHO clinical stages 3 or 4, or have absolute CD4 counts below 200 (until 2005) or 250/
μl in adults or the age dependent absolute or percent CD4 threshold in children. They attend
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a standardized session to understand the implications of ART, start ART with a 2 week lead
in phase with a lower dose of nevirapine (NVP) unless on TB treatment, and receive
monthly supplies of Triomune™. If adherence is good, patients receive ART for two months.
Monitoring and evaluation system
The monitoring and evaluation system has been described elsewhere [13–15]. The system is
based on tools recommended by WHO, including a master card for each ART patient and a
patient register at each facility. At ART initiation, clinicians enter date, type of regimen and
demographics on the patient’s treatment card and this information is later transcribed into
the ART register by a clerk. At each scheduled visit, the following primary outcomes are
assessed and recorded on the treatment card by the clinician or nurse: alive and on ART,
stopped all ART (for any reason, such as treatment fatigue or toxicity), LTFU (not been seen
in the clinic more than 2 months after dispensed drugs have run out), transferred to another
ART clinic, and death (based on a reliable report about the patient’s death). Secondary
outcomes included side effects, change of regimen and pill counts.
Outcomes are transcribed at least quarterly to the ART register and information is updated in
the register where appropriate. For example, a patient who was lost to follow-up and came
back to restart ART would be reclassified as alive and on ART, a patient found to receive
ART elsewhere would be classified as transferred out, and a patient found to have died
would be recorded as a death. A MoH supervision team, consisting of two trained
supervisors, visits each site quarterly and checks all treatment cards and ART site registers
for completeness and consistency [19]. The supervision teams aggregate data in quarterly
national reports. Since 2006, an Electronic Medical Records System using touchscreen
computers has been introduced at sites exceeding 2000 patients [20]. A recent audit of data
quality found that monitoring and evaluation of the ART programme was well organized
and produced good quality data [15].
Data collection
Between April and June 2008, two photography clerks visited all public and private ART
sites and photographed ART registers to create a set of digital images using 2 digital
cameras, four 2GB SD memory cards, 2 sets of re-chargeable batteries, chargers and 2
wooden camera frames (jigs) for fixed distance image collection. The jig allowed a constant
focal distance to ensure that the camera captured the entire page with maximum clarity. The
left and right pages were labelled with blue tags with page numbers to ensure proper pairing
of pages. Patients’ and guardians’ names and addresses were covered and were invisible on
the pictures to protect confidentiality. Images were enhanced and aligned using Google’s
Picasa™ –software for optimal data transcription; images were backed up on a 150 GB
external hard drive. Thereafter, six data clerks transcribed the data into an Excel database by
double entry using the enhanced digital images. The project manager supervised data entry
and conducted data validation, using the Excel Synkronizer plug-in. The database contained
the following variables: ART registration number and date of registration, age, sex, transfer,
date of starting ART, reason for ART, and primary outcomes with dates. The data from nine
sites with electronic records were merged with the database.
Study population
The analysis includes patients who started treatment between 1st January 2004 and 31st
December 2007 in the public sector through their first 12 months on ART and excludes
patients with unknown age, sex, start date and date and type of outcome (Figure 1). In
addition, patients of private sector sites had to be excluded since data quality was poor.
Patients who started ART elsewhere and were transferred in had to be excluded from the
analysis to avoid double counting: the program does not use a unique national identification
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number. Patients transferred out were censored at their last follow-up visit. We considered
three endpoints: mortality, LTFU and retention on ART, defined as the reciprocal of death,
LTFU and treatment stop combined.
Statistical analysis
We used competing risk models to analyze the time to LTFU and the time to death, as
measured from the start of ART (i.e. baseline) [21]. Competing risk analysis assumes that
each patient is exposed to two or more risks, which may not be independent. One of these
outcomes is the event of interest, while the others are competing events. The analyses were
censored one year after starting ART. The multivariable models included patient-level (age
group, gender, WHO stage and year of start) and clinic-level (degree of urbanization, region
and health facility level) variables. Age groups included infants 0–1 years of age, children
2–5 and 6–14 years, and adults 15–24, 25–34, 35–44 and ≥45 years. We investigated
possible interactions between age group and all other variables. Retention on ART was
analyzed by fitting a Cox proportional hazards regression model for outcomes death, LTFU
and stopping treatment combined, adjusted for the same variables as in the competing risk
analyses. Results are shown as sub-hazard ratios (sHR) from the competing risk analysis and
hazard ratios (HR) from the Cox regression, with 95% confidence intervals (95%CI).
In a separate analysis we used a web calculator developed by the International
epidemiological Databases to Evaluate AIDS (IeDEA, available at www.iedea-sa.org) to
obtain estimates of mortality that are corrected for LTFU. The calculations are based on the
fact that overall mortality is the average of mortality in patients retained in care and
mortality in patients lost to follow-up, weighted by the proportion of patients lost to follow-
up [22]. Mortality in patients LTFU was estimated based on a meta-analysis of studies that
assessed the vital status of patients by tracing them [23].
Confidentiality and ethical approval
Measures are in place in all ART facilities to ensure patient confidentiality, consent for HIV
testing, and counselling and support for those who receive a positive HIV test result. Studies
using data collected routinely within the context of monitoring and evaluation, such as ART
registers, do not require formal approval by the Malawi National Health Science Research
Committee.
RESULTS
The dataset included 189,931 patients from 211 clinics; 117,945 patients from 148 clinics
met the eligibility criteria and were analysed (Figure 1). The median age of patients was 34
years and 1.0% were infants <2 years, 7.4% children 2–14 years, 7.5% were young people
15 to 24 years and 84.2% were 25 years and older (Table 1). Sixty percent of all patients
were female and the gender ratio showed a characteristic pattern across age groups: women
outnumbered men from age 14 to 40 years, with a peak female-to-male ratio of 6.3 at the age
of 20 (web appendix Figure S1). The proportion of patients with WHO clinical stage 3 or 4
was similar for adults (85.8%), children 2–14 years (85.2%), and infants (84.4%). Between
2004 and 2007 the proportion of annual ART initiations that were in infants and children
increased from 6.0% to 9.6%.
The number of clinics grew steadily from 17 in January 2004 to 148 in December 2007 and
more patients started treatment each year: from 6,809 in 2004 to 51,810 in 2007, reaching
the cumulative number of 117,945 by December 2007 (Figure 2). Most clinics (n=66, 45%)
were in southern Malawi, where the majority of patients were started on ART (n=62,544,
53%). Though the majority of clinics were health centres (n=53, 36%), most adults (56%)
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and children 2–14 years (48%) started in district hospitals and clinics located in urban areas
(52% of adults and 48% of children, respectively, Table 1). Thirty-three clinics had only
adults and in two clinics the majority of patients were children and infants. Most ‘other’
facilities were run by Malawian non-governmental organisations.
Mortality, loss to follow-up and retention on ART
Patients were followed for a total of 85,246 person-years. At 12 months outcomes were as
follows: 81,980 (69.5%) patients were alive and on ART in the same clinic, 14,425 (12.2%)
had died, 11,827 (10.0%) were LTFU, 9,432 (8.0%) had transferred to another clinic and
281 (0.2%) had stopped ART.
Mortality rates in children and infants decreased from 24.3 per 100 person-years during the
period of the first 3 months on ART to 5.9 per 100 person-years during months 4 to 12; the
corresponding numbers for adults were 37.0 per 100 person-years and 8.0 per 100 person-
years. Figure 3A shows the mortality for the two periods by age at start of ART: infants <2
years (47.0 per 100 person-years) and young people aged 15–24 years (40.8 per 100 person-
years) had the highest early mortality. Infants and young people had also the highest rates
for LTFU over 12 months (24.7 and 19.3 per 100 person-years, respectively). As a result,
retention in these age groups was lowest, while children 6 to 14 years were most likely to
remain in care, followed by children aged 2–5 years (Figure 3B).
The higher mortality and LTFU rates in infants and young people were confirmed in the
multivariable analysis with adjusted sHRs for mortality of 1.37 (95%CI 1.17–1.60) in
infants and 1.17 (95%CI 1.10–1.25) in young people compared to adults 25 to 34 years. For
LTFU the corresponding sHRs were 1.37 (95%CI 1.18 to 1.59) and 1.27 (95%CI 1.19 to
1.35, Table 2). Male sex was associated with a faster progression to death and a higher risk
of LTFU, and this was particularly pronounced in adults 25–34 years of age (Figure 3C, 3D;
the sHR of mortality 1.50, 95%CI 1.42–1.59, p-value for interaction <0.001; sHR for LTFU
1.29, 95% CI 1.22 to 1.38, p-value for interaction <0.001). WHO stages 3 and 4 were
associated with higher mortality; this was more pronounced in adults of all ages compared to
children (p-value for interaction <0.001). Over calendar years, the risk of death decreased
whereas the risk of LTFU increased: the sHR comparing 2004 with 2007 was 1.65 (95%CI
1.54–1.76) for mortality and 0.56 (95%CI 0.51 to 0.62) for LTFU, resulting in a similar
probability of retention each year (Table 2; web appendix Figure S2). Finally, there were
differences between health care facilities. For example, mortality in central hospitals was
lower and LTFU higher in central hospitals compared to district hospitals.
Mortality corrected for loss to follow-up
Observed mortality rates for each clinic together with estimated rates of mortality that take
deaths among patients LTFU into account are presented in the web appendix (Figure S3).
Across all clinics, the median (interquartile range, IQR) observed mortality rate was
14.6/100 person-years (9.2 – 21.6). After correcting mortality for LTFU, the median (IQR)
mortality rate increased to 18.5/100 person-years (12.9 – 26.1).
DISCUSSION
Our analysis of patient-level data of the national ART programme in Malawi between 2004
and 2007 showed that infants less than 2 years and young people 15 to 24 years had the
highest mortality and LTFU rates in the first year of ART, in particular during the first 3
months, when mortality rates were up to 5 times higher than in the subsequent 9 months.
Multivariable regression confirmed that patients starting in these age groups had the highest
risk of death or LTFU. From the age of 20 years, men were more likely to die than women,
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with a 50% higher risk in those aged 25 to 34 years. Overall, there was a trend of decreasing
mortality from 2005 onwards, but LTFU increased across all age groups, and consequently
overall programme retention remained stable.
This country-wide study of ART clinics in the public sector, which in Malawi covers over
96% of all patients receiving ART, was highly representative and thus provides a
comprehensive picture of ART in the country. Data were produced in paper registers under
routine service conditions by providers on the ground, and their quality was assessed
quarterly by Ministry of Health teams. To our knowledge this is the largest data set from a
single country that includes adults and children and allows the examination of clinic-level
and patient-level risk factors. Our analysis thus extends studies of national ART
programmes that were limited to geographical regions [8, 24], a sample of sites [12],
aggregated data [14, 25], and specific providers, such as nongovernmental organisations [7,
9]. We present outcomes across all ages in one analysis, reflecting the integrated nature of
care in Malawi, and thus make valid comparisons between age groups possible.
The mortality in our cohort was higher compared to other paediatric [5, 26] and adult [8]
studies. A comparable early mortality rate in infants was reported from Côte d’Ivoire [4] and
Malawi [27]. In 2004–5, at primary care facilities in Lusaka in neighbouring Zambia, the
overall mortality in adults was less than in our national cohort with 16.1/100 person-years,
but younger people 15–29 years also had the highest mortality rate among adults (17.2/100
person-years). The early mortality in this age group was 25.6/100 person-years, considerably
lower than in our study [8]. This might be caused by differences in baseline characteristics,
quality of care or deaths not accounted for among patients LTFU. Recent data from
Tanzania’s national ART programme report poor retention of young people on ART who
had advanced disease at ART initiation [28].
We found decreasing mortality and increasing LTFU over the four years of this study,
resulting in overall a stable retention of patients on ART over time. This pattern was also
observed in four provinces in South Africa [29], where errors in the documentation of
patients transferred out and insufficient capacity to manage the many patients contributed to
the higher rates of LTFU. Our dataset included no information on individual visits: only the
most recent outcome was recorded for each patient. Patients who became lost to follow-up
recently therefore had less time to return to the clinic than patients lost in earlier years. This
could partly explain the increase in the rate of LTFU in more recent years, but the bias is
likely to be small: a study from Zambia found that the 60-day threshold for the number of
days patients could be late for an appointment before being classified as LTFU performed
well, with a sensitivity of 84% and misclassification of only about 5% of patients [30]. The
change of policy in the treatment of HIV/TB co-infected patients may have contributed to
the decline in mortality. Before 2006, HIV/TB patients had to wait with ART until
completion of TB treatment or had to stop and restart ART, when TB was diagnosed while
on ART. In 2006 co-treatment of HIV and TB was introduced [31].
Our study relied on routine operational data collected during normal service provision. With
high workloads, errors are unavoidable, but routine supervision should have minimized their
frequency. Of note, the dataset was limited to the variables required for national monitoring.
It is well known that CD4 count and viral load as well as socioeconomic and anthropometric
parameters are associated with patients’ outcomes, but we could not examine these variables
as they were not a part of our core dataset. We also did not collect information on
cotrimoxazole prophylaxis, AIDS-related diseases such as Kaposi’s sarcoma and
tuberculosis, or prior exposure to antiretroviral prophylaxis as part of prevention of mother
to child transmission (MTCT). By excluding patients who transferred in at ART sites we
may have introduced some bias, since patients who move between clinics may have
Weigel et al. Page 6
AIDS. Author manuscript; available in PMC 2013 October 29.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
different outcomes compared to patients who stay in care at the same site [32]. Our method
of taking photographs of ART registers using a simple digital camera supported by a jig, to
standardize distance and focus is a novel and untested approach. However, the method was
piloted, and all photographs were reviewed twice and data entry errors corrected.
In conclusion, routine data from Malawi’s ART monitoring and evaluation system not only
provide useful aggregated data to guide policy [33], but also patient level data that
specifically point to the needs of infants, young people and men, extending previous
findings [34–36]. Malawi national guidelines have now adopted the new WHO
recommendations to start adults and children earlier on ART [33], and go beyond WHO
recommendations in the prevention of MTCT [37]. Late presentation and start of ART may
be one reason for poor outcomes both in young people and men [38, 39]. Unfortunately,
outcomes of men on ART have received little attention, despite increasing evidence that in
sub-Saharan Africa their prognosis is poorer than in women [40]. Gender norms may
prevent men to seek health care early or make them feel uncomfortable admitting ill health,
resulting in lower and later uptake of ART [35, 41]. Male champions, popular men
advocating for a change in behaviour, may have an impact [41]. Several factors facilitating
access to health services have been identified in young people [42]: services should be free,
respect young people’s need for privacy and involve them in decision making. In Zambian
children on ART, factors associated with poor adherence included changing residence,
school attendance, lack of HIV disclosure to the child, and increasing household income
[43]. ART programs should collaborate more closely with schools, and with youth-friendly
services in the community [44, 45], for example teen clubs [44], and involve these services
in efforts to improve retention on ART.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Flowchart of patients included
The figures in brackets give the number of adults aged ≥ 15 years/the number of infants and
children aged 0–14 years.
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Figure 2. Number of clinics and cumulative number of patients (dashed black line) starting ART
between 2004 and 2007
* Facilities run by non-governmental organizations or armed forces, occupational clinics
Weigel et al. Page 12
AIDS. Author manuscript; available in PMC 2013 October 29.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
Figure 3. Mortality and loss to follow-up within one year of starting antiretroviral therapy
A: Mortality rates per 100 person-years with 95% confidence intervals in months 1–3 and
months 4–12 months after start of antiretroviral therapy by age group.
B: Kaplan-Meier probability of retention on ART over the first year on ART for different
age groups.
C and D: Mortality and LTFU rates per 100 person-years by age at start of ART and sex.
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Table 1
Patient characteristics at start of antiretroviral therapy
N %
Age (years)
 0-1 1178 1.0%
 2-5 3737 3.2%
 6-14 4951 4.2%
 15-24 8821 7.5%
 25-34 40703 34.5%
 35-44 36342 30.8%
 45- 22213 18.8%
Gender
 Female 71247 60.4%
 Male 46698 39.6%
WHO stage at start
 I or II 16813 14.3%
 III or IV 101132 85.7%
Year of starting ART
 2004 6809 5.8%
 2005 21378 18.1%
 2006 37948 32.2%
 2007 51810 43.9%
Region
 Northern 16536 14.0%
 Central 38865 33.0%
 Southern 62544 53.0%
Degree of urbanization
 Urban 60688 51.5%
 Semiurban 21069 17.9%
 Rural 36188 30.7%
Health care facility
 Central hospital 16414 13.9%
 District hospital 65363 55.4%
 Rural hospital 5317 4.5%
 Health centre 14018 11.9%
 Others* 16833 14.3%
TOTAL 117945 100.0%
*Non-governmental Organizations, armed forces, occupational clinics
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